Investor relations

Investor relations

Our science-led strategy is key to delivering long-term value for patients, employees and shareholders.

NYSE: MRK
February 9, 2023 12:31 am ET
Delayed at least 20 minutes

Latest news, events & financials

February 3, 2023

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma

February 2, 2023

Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results

January 27, 2023

FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)

View all

March 06, 2023

Webcast

Merck & Co., Inc. Cardiovascular Investor Event at ACC.23/WCC

Add to Calendar

April 27, 2023

Earnings

Merck & Co., Inc. Q1 2023 Earnings Call

Add to Calendar

August 01, 2023

Earnings

Merck & Co., Inc. Q2 2023 Earnings Call

Add to Calendar

October 26, 2023

Earnings

Merck & Co., Inc. Q3 2023 Earnings Call

Add to Calendar

View all

4Q22 Merck Earnings Announcement
PDF

4Q22 Merck Other Financial Disclosures
PDF

View all

Merck & Co., Inc. Cardiovascular Investor Event at ACC.23/WCC

Add to Calendar

See full agenda

Our pipeline shows our relentless pursuit of the next breakthrough.

Explore our pipeline

Phase II programs

Phase III programs

Under review

Illustration of leaders speaking on stage

Our leadership

Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy.

Leadership

Environmental, Social & Governance (ESG)

Supporting the future of our business and the health and well-being of patients, people and communities around the world.

Download our 2021/2022 ESG Progress Report

Download our ESG financing documents:

2021 Sustainability financing framework

Second-party opinion (SPO) on the bond framework

2022 Sustainability bond allocation report

We're led by our science

We follow the science to our next breakthrough, leaving no stone unturned.

View our stories

Innovation

Merck’s Q4 and full-year 2022 earnings report

Merck’s (NYSE: MRK) Q4 and full-year 2022 results reflect sustained strong revenue growth. The company announced Q4 worldwide sales of $13.8 billion, an increase of 2% from Q4 2021. Full-year 2022 worldwide sales were $59.3 billion, an increase of 22% from full year 2021. “2022 was an exceptional year for Merck, which is a testament […]

Next: Merck’s Q4 and full-year 2022 earnings report